Announcements Trials
Browse Landscape

Phase

Phase NA 3Phase 2 2Phase 1 2

Status

Completed 36Recruiting 7Active not recruiting 5Terminated 4Withdrawn 2Unknown 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Sarcoma 2Genitourinary 2CNS 2Lymphoid 1

Conditions

Neoplasms 57Breast Neoplasms 52Leukemia, Myeloid, Acute 40Carcinoma, Non-Small-Cell Lung 40Lymphoma 35Pancreatic Neoplasms 30Leukemia, Lymphocytic, Chronic, B-Cell 30Leukemia 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 27Neoplasm Metastasis 27Ovarian Neoplasms 25Multiple Myeloma 25Lymphoma, Non-Hodgkin 25Recurrence 24Lung Neoplasms 23Melanoma 22Lymphoma, Large B-Cell, Diffuse 21Prostatic Neoplasms 20Glioblastoma 20Brain Neoplasms 19Colorectal Neoplasms 18Lymphoma, Follicular 17Squamous Cell Carcinoma of Head and Neck 16Sarcoma 16Lymphoma, B-Cell 15Lymphoma, Mantle-Cell 14Myelodysplastic Syndromes 13Urinary Bladder Neoplasms 12Lymphoma, B-Cell, Marginal Zone 12Glioma 12

Interventions

pazopanib 1Dexamethasone 12,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Withdrawn × Wilms Tumor × Clear all
NCT01130623 2017-07-02

A Phase I Study of Pazopanib as a Single Agent for Children With Refractory Solid Tumors

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNSGenitourinarySarcoma

Brain Neoplasms, Neoplasms, Wilms Tumor, Neuroblastoma, Sarcoma, Osteosarcoma

NCT01236586 2017-07-02

RO4929097 in Children With Relapsed/Refractory Solid or CNS Tumors, Lymphoma, or T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
CNSGenitourinaryLymphoidSarcoma

Brain Neoplasms, Lymphoma, Neoplasms, Wilms Tumor, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡